Home › Funds › Trails Edge Capital Partners, LP › LBRX
Trails Edge Capital Partners, LP position in LBRX
LB PHARMACEUTICALS INC · Health Care
Trails Edge Capital Partners, LP reported holding 1,523,022 shares of LBRX (LB PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$49.4M, representing 7.85% of its reported portfolio and ranking #1 among its reported holdings. Trails Edge Capital Partners, LP has disclosed LBRX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Trails Edge Capital Partners, LP's LBRX position evolved
Trails Edge Capital Partners, LP first disclosed a stake in LBRX in Q4 2025 at 1,395,608 shares (US$31.1M). The position peaked in Q2 2026 at 1,523,022 shares, worth US$49.4M. Across 3 filings, Trails Edge Capital Partners, LP increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,523,022 shares valued at US$49.4M — an increase of 203,660 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 1.40M | $31.07M | New |
| Q1 2026 | 1.32M | $32.54M | Reduce |
| Q2 2026 | 1.52M | $49.43M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About LBRX and 13F data
LBRX (LB PHARMACEUTICALS INC) is a Health Care company. 110 other funds we track also report a position in LBRX — the largest reported positions include Deep Track Capital, LP (US$108.8M), RA CAPITAL MANAGEMENT, L.P. (US$71.7M), Commodore Capital LP (US$48.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding LBRX
- Deep Track Capital, LP 3.35M sh · $108.82M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 2.21M sh · $71.68M · Q2 2026
- Commodore Capital LP 1.50M sh · $48.68M · Q2 2026
- TCG Crossover Management, LLC 1.45M sh · $46.97M · Q2 2026
- Caligan Partners LP 1.44M sh · $46.67M · Q2 2026
- Spruce Street Capital LP 1.38M sh · $44.66M · Q2 2026
- Nantahala Capital Management, LLC 1.05M sh · $34.17M · Q2 2026
- Vivo Capital, LLC 800.00K sh · $25.96M · Q2 2026
- Nan Fung Group Holdings Ltd 630.66K sh · $20.47M · Q2 2026
- Logos Global Management LP 585.00K sh · $18.99M · Q2 2026
- GREAT POINT PARTNERS LLC 317.22K sh · $10.30M · Q2 2026
- HighVista Strategies LLC 211.51K sh · $6.86M · Q2 2026
More on Trails Edge Capital Partners, LP
FAQ
How long has Trails Edge Capital Partners, LP held LBRX?
Trails Edge Capital Partners, LP has disclosed LBRX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Trails Edge Capital Partners, LP's current position in LBRX?
As of Q2 2026, Trails Edge Capital Partners, LP holds 1.52M shares of LBRX (LB PHARMACEUTICALS INC), valued at $49.43M, representing 7.85% of its reported portfolio and ranking #1.
Has Trails Edge Capital Partners, LP been buying or selling LBRX?
In the latest 13F filing (Q2 2026), Trails Edge Capital Partners, LP increased its position in LBRX. The position peaked in Q2 2026 at 1.52M shares.
Which other funds hold LBRX?
Other major institutional holders of LBRX include Deep Track Capital, LP, RA CAPITAL MANAGEMENT, L.P., Commodore Capital LP, among 110 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.